Message

Leveraging our R&D capabilities, RaQualia has successfully ushered in one human therapeutic and three veterinary medicines to the market. Additionally, we have strategically licensed over ten developmental assets to partner companies, with their preclinical and clinical evaluation currently underway. We are proud of our position as a leading Japanese biotechnology venture, distinguished by our exceptional R&D track record.

 

RaQualia's core competency resides in the area of small molecule drug discovery. Notably, we have achieved significant milestones in ion channel drug discovery by harnessing the power of our veteran-level expertise in small molecule drug design and synthesis, coupled with cutting-edge electrophysiology technologies. However, the scientific and technological landscape is undergoing a far-reaching transformation, rendering drug discovery methodologies susceptible to obsolescence unless continuously approached with the latest advancements.

 

In recognition of these urgent needs, our scientists engage in an ever-evolving process of knowledge augmentation, meticulously integrating the most recent scientific discoveries and pioneering technological innovations into our workflows. Notably, we are actively pursuing the automation of small molecule drug synthesis and the modernization of our electrophysiology platforms. Furthermore, we have embarked on a collaborative drug discovery program focused on the development of small molecule inhibitors designed to suppress mRNA translation.

 

Given the understood challenges surrounding the use of small molecule compounds, we advocate for the adoption of "new modalities" as a cornerstone solution. To facilitate this, we have established a satellite laboratory within Shonan iPark, fostering collaborations with domestic and international biotechnology ventures, as well as academic institutions. RaQualia's renewed vision is to "become the world’s leading innovators who deliver advanced medicines to patients with intractable diseases”. Through our dedication to science-driven drug discovery and the pursuit of R&D excellence, we aim to ensure the uninterrupted development of life-changing therapeutics that address underserved medical needs.

 

Katsuhiro Uto
Head of Research and Development